Tobevibart

DRUG3 trials

Sponsors

Vir Biotechnology, Inc.

Conditions

Viral Hepatitis

Phase 2

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

Active, not recruitingNCT07142811

Vir Biotechnology, Inc.Viral Hepatitis

Start: 2025-08-05End: 2030-07-01Target: 100Updated: 2026-01-16

Phase 3

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

Active, not recruitingNCT06903338

Vir Biotechnology, Inc.Viral Hepatitis

Start: 2025-03-12End: 2031-05-01Updated: 2026-04-08

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

Active, not recruitingNCT07128550

Vir Biotechnology, Inc.Viral Hepatitis

Start: 2025-07-30End: 2031-07-01Target: 150Updated: 2026-07-13